2225 — Jinhai Medical Technology Income Statement
0.000.00%
Last trade - 00:00
- HK$5.17bn
- HK$5.07bn
- SG$45.64m
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 51.9 | 22.5 | 21.9 | 22.3 | 45.6 |
Cost of Revenue | |||||
Gross Profit | 12.4 | 8.85 | 7.73 | 10.1 | 12 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 51.4 | 20.7 | 21.8 | 21.4 | 48.6 |
Operating Profit | 0.521 | 1.74 | 0.07 | 0.869 | -3 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 0.086 | 1.43 | -0.062 | 0.784 | -3.22 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.686 | 1.26 | -0.498 | 0.116 | -4.11 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -0.686 | 1.26 | -0.246 | 0.468 | -3.14 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.686 | 1.26 | -0.246 | 0.468 | -3.14 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.001 | -0 | -0.001 | 0 | -0.003 |